Evidence map›Paper›PMID 32052079›Full record

ArticleCancer immunology, immunotherapy : CII2020

Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.

Anne Fröhlich, Dennis Niebel, Simon Fietz, Eva Egger, Andrea Buchner, Judith Sirokay, Jennifer Landsberg

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Signal pathways of melanoma and targeted therapy.Signal transduction and targeted therapy · 2021
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Anne FröhlichDepartment of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Str. 25, Venusberg-Campus 1, 53127, Bonn, Germany.
Dennis NiebelDepartment of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Str. 25, Venusberg-Campus 1, 53127, Bonn, Germany.
Simon FietzDepartment of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Str. 25, Venusberg-Campus 1, 53127, Bonn, Germany.
Eva EggerDepartment of Gynecology, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany.
Andrea BuchnerDepartment of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Str. 25, Venusberg-Campus 1, 53127, Bonn, Germany.
Judith SirokayDepartment of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Str. 25, Venusberg-Campus 1, 53127, Bonn, Germany.
Jennifer LandsbergDepartment of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Str. 25, Venusberg-Campus 1, 53127, Bonn, Germany. jenny.landsberg@ukbonn.de.ORCID http://orcid.org/0000-0001-8029-3883
University of Bonn · DE

Funding

DFG EXC 1023
6 · The paper itself

Abstract

backgroundResistance to immune checkpoint blockade and targeted therapy in melanoma patients is currently one of the major clinical challenges. With the approval of talimogene laherparepvec (T-VEC), oncolytic viruses are now in clinical practice for locally advanced or non-resectable melanoma. Here, we describe the usage of T-VEC in stage IVM1b-M1c melanoma patients, who achieved complete remission or stable disease upon systemic treatment but suffered from a loco-regional recurrence. To our knowledge, there are no case reports so far describing T-VEC as a means to overcome acquired resistance to immune checkpoint blockade or targeted therapy.

methodsAll melanoma patients in our department treated with T-VEC in the period of 2016-2018 were evaluated retrospectively. Data on clinicopathological characteristics, treatment response, and toxicity were analyzed.

resultsFourteen melanoma patients were treated with T-VEC in our center. Six patients (43%) received T-VEC first-line. In eight patients (57%), T-VEC followed a prior systemic therapy. Three patients with M1b stage and one patient with M1c stage melanoma were treated with T-VEC. These patients suffered from loco-regional progress, whilst distant metastases had regressed during prior systemic treatment. 64% of patients showed a benefit from therapy with T-VEC. The durable response rate was 36%.

conclusionT-VEC represents an effective and tolerable treatment option. This is true not only for loco-regionally advanced melanoma patients, but also for patients with stable or regressive systemic metastases who develop loco-regionally acquired resistance upon treatment with immune checkpoint blockade or targeted therapy. A sensible selection of suitable patients seems to be crucial.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalBiological ProductsCostimulatory and Inhibitory T-Cell ReceptorsDisease ProgressionDrug Resistance, NeoplasmFemaleFollow-Up StudiesHerpesvirus 1, HumanHumansImmunotherapyMaleMelanomaMiddle AgedAntineoplastic Agents, ImmunologicalBiological ProductsCostimulatory and Inhibitory T-Cell Receptorstalimogene laherparepvecAcquired resistanceAdvanced melanomaImmunotherapyTalimogene laherparepvecTargeted therapy

Identifiers

PMID32052079
PMCPMC7183503
OpenAlexW3006513742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.